Navigation Links
Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
Date:9/4/2007

Results Further Validate Lipidomic-Based Therapeutics as an Emerging Area

of Drug Discovery

SAN DIEGO, Sept. 4 /PRNewswire-FirstCall/ -- Lpath, Inc. (OTC Bulletin Board: LPTN), the category leader in therapeutic agents against bioactive lipids, reported positive results in several murine models of human cancer and AMD with Lpathomab(TM), the company's mouse monoclonal antibody against LPA (lysophosphatidic acid). These results confirm the expected potent anti-angiogenic and anti-metastatic actions of Lpathomab. Lpathomab was created using Lpath's proprietary ImmuneY2(TM) platform technology.

Based on this positive outcome, Lpath will collaborate with DataMabs of London, England, to humanize Lpathomab to create a lead antibody for pre- clinical development.

LPA is a bioactive lipid long recognized as a significant promoter of cancer-cell growth and metastasis in a broad range of tumor types, as well as a significant contributor to neuropathic pain.

"Humanizing our Lpathomab antibody is a vital next step in moving the project into the clinic," said Genevieve Hansen, Ph.D., Lpath's vice president of research. "We've had great success in the past working with DataMabs and look forward to working with them again on our Lpathomab project."

This achievement with Lpathomab comes on the heels of Lpath's success with its Sphingomab(TM) program. Sphingomab is an antibody against another bioactive lipid, S1P. Lpath humanized the antibody in 2006 and plans to file an IND in November of this year for the use of ASONEP(TM) (the systemic formulation of humanized Sphingomab) for the treatment of cancer. It also plans to file a second IND early next year for the use of iSONEP(TM) (the ocular formulation of humanized Sphingomab) for the treatment of AMD. The company plans to submit an IND filing for the use of humanized Lpathomab in 2009.

Dr. Roger Sabbadini, the founder and CSO of Lpath, commented, "These excitin
'/>"/>

SOURCE Lpath, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Lpath Demonstrates First-in-Class AMD Results With Its Lead Drug Candidate, Sphingomab
2. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
3. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
4. New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines
5. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
6. Gerons Telomerase Inhibitor Cancer Drug Demonstrates Good Pharmacokinetics and Tolerability in Phase I/II Trial
7. Frova Phase III Study Data Demonstrates That Short-Term Prevention Treatment Reduces Frequency and Severity of Menstrual Migraine
8. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
9. Cipralex demonstrates superiority to duloxetine for acute treatment of depression in new study
10. Newly Published Data Demonstrates Superiority of Cipralex Over Duloxetine for Acute Treatment of Depression
11. Introgens Advexin Demonstrates Clinical Benefit in Inherited Cancer

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/5/2009)...FirstCall/ -- Osteotech, Inc. (Nasdaq: OSTE ), a ...for regenerative healing, today reported financial... 2009. ,, "During the third quarter of 2009, ou...ic products MagniFuse(TM) Bone Graft, FacetLinx(T... Grafting," said Sam Owusu-Akyaw, President and Ch...
(Date:11/5/2009)...wswire-FirstCall/ -- Transcept Pharmaceuticals, In...mpany focused on the development and commercializa...t therapeutic needs in the field of neuroscience, ...ference with management to discuss third quarter 2...09, at 5:00 p.m. Eastern Standard Time. Financial...
(Date:11/5/2009)... ARKRAY, Inc., the world,s 5th largest manufacture...nced that it has received 510(k) clearance from th...OCARD Vital blood glucose monitoring system. ,,...ll make available for distribution in early Decemb...the existing GLUCOCARD line of products, and will ...
Breaking Medicine Technology:Osteotech Reports Third Quarter 2009 Financial Results 2Osteotech Reports Third Quarter 2009 Financial Results 3Osteotech Reports Third Quarter 2009 Financial Results 4Osteotech Reports Third Quarter 2009 Financial Results 5Osteotech Reports Third Quarter 2009 Financial Results 6Osteotech Reports Third Quarter 2009 Financial Results 7Osteotech Reports Third Quarter 2009 Financial Results 8Transcept Pharmaceuticals to Report Third Quarter 2009 Results and Host Conference Call on November 12 2ARKRAY, Inc. Receives FDA Clearance for New GLUCOCARD(R) Vital(TM) Blood Glucose Monitoring System 2Clinical Trials Move to Emerging Regions Heighten Need for Local Risk Consulting 3A Aon Global Risk Map 14121 1Clinical Trials Move to Emerging Regions Heighten Need for Local Risk Consulting 3A Aon Global Risk Map 14121 2Clinical Trials Move to Emerging Regions Heighten Need for Local Risk Consulting 3A Aon Global Risk Map 14121 3Clinical Trials Move to Emerging Regions Heighten Need for Local Risk Consulting 3A Aon Global Risk Map 14121 4Clinical Trials Move to Emerging Regions Heighten Need for Local Risk Consulting 3A Aon Global Risk Map 14121 5UCSF scientists illuminate how microRNAs drive tumor progression 57501 1UCSF scientists illuminate how microRNAs drive tumor progression 57501 2UCSF scientists illuminate how microRNAs drive tumor progression 57501 3New research to unravel how nutrients drive toxic brown tides on East Coast 9965 1New research to unravel how nutrients drive toxic brown tides on East Coast 9965 2
...e Society International Congress, SOUTH PLAINFIEL...biopharmaceutical company focused on the discovery...ule drugs targeting,post-transcriptional control m...Phase 2 clinical trial of PTC124 in patients with ...e mutation. The results, which include data,from a...
...ticals, Inc.,(OTC Bulletin Board: ACCP) announced ...inical and preclinical data on its lead anticancer... the American Association for,Cancer Research (AAC...rganization for Research and Treatment of Cancer (...r Targets and Cancer Therapeutics:,Discovery, Biol...
Other Medicine Technology:PTC Therapeutics Announces Additional Results from Phase 2 Study of PTC124 in Duchenne Muscular Dystrophy 2PTC Therapeutics Announces Additional Results from Phase 2 Study of PTC124 in Duchenne Muscular Dystrophy 3PTC Therapeutics Announces Additional Results from Phase 2 Study of PTC124 in Duchenne Muscular Dystrophy 4Access Pharmaceuticals to Present Data on ProLindac(TM) at the AACR-NCI-EORTC 'Molecular Targets and Cancer Therapeutics' Conference 2
(Date:11/9/2009)... Only 5 percent of seniors have changed Medicare...better service and improved coverage among biggest...eason nears , , Bellevill...cent of seniors have changed their Medicare plan s...rcent) report they are likely to or are considerin...
(Date:11/9/2009)...ifted young athletes are under increasing pressure...Loyola University Health System study of 519 junio...n increases the risk of injury. Researchers who an...iation junior competition found that players who s...draw from tournaments for medical reasons, typical...
(Date:11/8/2009)...8 Jon O,Brien, presiden...atement about the passage of HR 3962: ,, "Beha...ers a lot about core values. We in the prochoice c...o overcome the struggles ordinary Americans have m...nnot afford basic healthcare or have to choose bet...
(Date:11/8/2009)...t position promotes self-assurance, research finds...Your mother may have been right when she told you ...d posture could make you feel more confident about... sitting up straight gives a good impression to ot... and a psychology professor at Ohio State Universi...
(Date:11/8/2009)...8 Speaker Nancy Pelosi ...lowing the House passage of H.R. 3962, the Afforda...by a vote of 220 to 215. Below are the Speaker,s ...es just received a call from the President of the ...a great victory for the American people. I thank t...
Breaking Medicine News(10 mins):Health News:Few Change Medicare Plans Each Year, But Three Times as Many Are Considering a Change in 2010, Allsup Survey Finds, 2Health News:Few Change Medicare Plans Each Year, But Three Times as Many Are Considering a Change in 2010, Allsup Survey Finds, 3Health News:Few Change Medicare Plans Each Year, But Three Times as Many Are Considering a Change in 2010, Allsup Survey Finds, 4Health News:Few Change Medicare Plans Each Year, But Three Times as Many Are Considering a Change in 2010, Allsup Survey Finds, 5Health News:Young tennis players who play only 1 sport are more prone to injuries 2Health News:Catholics for Choice Statement on Healthcare Reform Bill 2Health News:Good Posture May Inspire Confidence 2
...e 47th Annual Meeting of the American Society for ...rado say that there is no direct link //between th...ess of prostate cancer, but the long-term survival...bsequent intensity of prostate cancer. Previous st...
...s the risk of colorectal tumours, while drinking w...study. // The study, conducted by Joseph C. A...sity, Stony Brook, New York, was meant to examine ...ients were subject to a survey of drinking habits ...
...from United Kingdom have found a new antibiotic ti...ation of Tetracycline known as Glycycline. // ... an increased incidence of antibiotic resistance s...tions in hospital. Staphylococcus aureus as shown ...
... interstitial fluid pressure (IFP) is negative, an... exposed, fluid does not seep out. //By contrast, ... barrier against efficient drug delivery into the ...itial space by convection (i.e. by streaming of a ...
...oor families who get fed in schools by the governm...ke up for their iron and vitamin deficiencies//. ...n pills, which have not found wide acceptance. Bes...a. The nutrition candy however should be seen as a...
...er is designated as the Breast Cancer Awareness Mo...hat despite the exponential morbidity and mortalit...d women are aware of what actually happens, what a...r Research Foundation, and Alexandra Penney, forme...
Other Medicine News:Health News:Alcohol Drinking Affects Risk Of Colorectal Tumours 2Health News:Tigecycline – New Generation Tetracycline With Broad Spectrum Antibacterial Activit 2Health News:A Novel Method For Measuring Interstitial Fluid Pressure In Cancer Tissues 2Health News:Vitamin filled nutrition candy for School children 2
Cindy Wrist Support
3-Point® Polycentric Hinged Ulnar Deviation Splint
...lint immobilizes and positions the elbow at 122 so... full extension and flexion to minimize stretching...ritation due to contracture. Also for ulnar nerve ...ensity beige polyethylene shell with plush 3/8"-th...
... Orthosis For quick, efficient immobilization of c...bilizes and protects the fracture and surrounding ..., support, and conformity to the fracture volume. ...ed (with heat gun) and reshaped. Sized to accommod...
Medicine Products: